Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. 2003
  2. Published

    Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

    Meier, J. J., Gallwitz, B., Siepmann, N., Holst, Jens Juul, Deacon, Carolyn F., Schmidt, W. E. & Nauck, M. A., Jun 2003, In : Diabetologia. 46, 6, p. 798-801 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 2004
  4. Published

    Circulation and degradation of GIP and GLP-1

    Deacon, Carolyn F., 2004, In : Hormone and Metabolic Research. 36, p. 761-765

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

    Holst, Jens Juul & Deacon, Carolyn F., 2004, In : Current Opinion in Pharmacology. 4, 6, p. 589-96 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

    Deacon, Carolyn F., Ahrén, B. & Holst, Jens Juul, 2004, In : Expert Opinion on Investigational Drugs. 13, 9, p. 1091-102 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs.

    Trebbien, R., Klarskov, L., Olesen, M., Holst, Jens Juul, Carr, R. D. & Deacon, Carolyn F., 2004, In : American Journal of Physiology: Endocrinology and Metabolism. 287, 3, p. E431-8

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

    Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, Jens Juul, Deacon, Carolyn F., Gallwitz, B., Schmidt, W. E. & Meier, J. J., 2004, In : Regulatory Peptides. 122, 3, p. 209-17 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.

    Meier, J. J., Nauck, M. A., Kranz, D., Holst, Jens Juul, Deacon, Carolyn F., Gaeckler, D., Schmidt, W. E. & Gallwitz, B., 2004, In : Diabetes. 53, 3, p. 654-62 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

    Meier, J. J., Gallwitz, B., Kask, B., Deacon, Carolyn F., Holst, Jens Juul, Schmidt, W. E. & Nauck, M. A., 2004, In : Diabetes. 53 Suppl 3, p. S220-4

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.

    Rolin, B., Deacon, Carolyn F., Carr, R. D. & Ahrén, B., 2004, In : European Journal of Pharmacology. 494, 2-3, p. 283-8 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. Published

    Therapeutic strategies based on glucagon-like peptide 1.

    Deacon, Carolyn F., 2004, In : Diabetes. 53, 9, p. 2181-9 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...22 Next

ID: 9220